Disruption	O
of	O
a	O
-	O
35	O
kb	O
Enhancer	O
Impairs	O
CTCF	O
Binding	O
and	O
MLH1	O
Expression	O
in	O
Colorectal	O
Cells	O
.	O


Purpose	O
:	O
MLH1	O
is	O
a	O
major	O
tumor	S-DISEASE
suppressor	O
gene	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Lynch	B-DISEASE
syndrome	E-DISEASE
and	O
various	O
sporadic	B-DISEASE
cancers	E-DISEASE
.	O


Despite	O
their	O
potential	O
pathogenic	O
importance	O
,	O
genomic	O
regions	O
capable	O
of	O
regulating	O
MLH1	O
expression	O
over	O
long	O
distances	O
have	O
yet	O
to	O
be	O
identified	O
.	O
Experimental	O
Design	O
:	O
Here	O
,	O
we	O
use	O
chromosome	O
conformation	O
capture	O
(	O
3C	O
)	O
to	O
screen	O
a	O
650	O
-	O
kb	O
region	O
flanking	O
the	O
MLH1	O
locus	O
to	O
identify	O
interactions	O
between	O
the	O
MLH1	O
promoter	O
and	O
distal	O
regions	O
in	O
MLH1	O
-	O
expressing	O
and	O
nonexpressing	O
cells	O
.	O


Putative	O
enhancers	O
were	O
functionally	O
validated	O
using	O
luciferase	O
reporter	O
assays	O
,	O
chromatin	O
immunoprecipitation	O
,	O
and	O
CRISPR	O
-	O
Cas9	O
-	O
mediated	O
deletion	O
of	O
endogenous	O
regions	O
.	O


To	O
evaluate	O
whether	O
germline	O
variants	O
in	O
the	O
enhancer	O
might	O
contribute	O
to	O
impaired	O
MLH1	O
expression	O
in	O
patients	O
with	O
suspected	O
Lynch	B-DISEASE
syndrome	E-DISEASE
,	O
we	O
also	O
screened	O
germline	O
DNA	O
from	O
a	O
cohort	O
of	O
74	O
patients	O
with	O
no	O
known	O
coding	O
mutations	O
or	O
epimutations	O
at	O
the	O
MLH1	O
promoter	O
.	O
Results	O
:	O
A	O
1	O
.	O
8	O
-	O
kb	O
DNA	O
fragment	O
,	O
35	O
kb	O
upstream	O
of	O
the	O
MLH1	O
transcription	O
start	O
site	O
enhances	O
MLH1	O
gene	O
expression	O
in	O
colorectal	O
cells	O
.	O


The	O
enhancer	O
was	O
bound	O
by	O
CTCF	O
and	O
CRISPR	O
-	O
Cas9	O
-	O
mediated	O
deletion	O
of	O
a	O
core	O
binding	O
region	O
impairs	O
endogenous	O
MLH1	O
expression	O
.	O


A	O
total	O
of	O
5	O
.	O
4	O
%	O
of	O
suspected	O
Lynch	B-DISEASE
syndrome	E-DISEASE
patients	O
have	O
a	O
rare	O
single	O
-	O
nucleotide	O
variant	O
(	O
G	O
>	O
A	O
;	O
rs143969848	O
;	O
2	O
.	O
5	O
%	O
in	O
gnomAD	O
European	O
,	O
non	O
-	O
Finnish	O
)	O
within	O
a	O
highly	O
conserved	O
CTCF	O
-	O
binding	O
motif	O
,	O
which	O
disrupts	O
enhancer	O
activity	O
in	O
SW620	O
colorectal	O
carcinoma	O
cells	O
.	O
Conclusions	O
:	O
A	O
CTCF	O
-	O
bound	O
region	O
within	O
the	O
MLH1	O
-	O
35	O
enhancer	O
regulates	O
MLH1	O
expression	O
in	O
colorectal	O
cells	O
and	O
is	O
worthy	O
of	O
scrutiny	O
in	O
future	O
genetic	O
screening	O
strategies	O
for	O
suspected	O
Lynch	B-DISEASE
syndrome	E-DISEASE
associated	O
with	O
loss	O
of	O
MLH1	O
expression	O
.	O


Clin	O
Cancer	O
Res	O
;	O
24	O
(	O
18	O
)	O
;	O
4602	O
-	O
11	O
.	O


2018	O
AACR	O
.	O
